HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC

NCT07700082 | Completed

• 1 other identifier: 2026KY245
• Study Type: observational
• Target: 555
• Locations: 1 country
• Sites: 1

Brief Summary

This is a completed multi-center retrospective observational study focusing on patients who received curative surgical resection for hepatocellular carcinoma (HCC). We collected anonymized historical clinical data, preoperative gadoxetic acid-enhanced MRI scans and digital pathological whole-slide images from three Chinese medical centers and the public TCGA-LIHC database. We developed a multimodal hybrid deep learning prognostic model (named HCC-MPDS) integrating multi-source medical data to stratify HCC patients into high-risk and low-risk recurrence groups after surgery. The primary goal of this study is to compare postoperative recurrence-free survival (RFS) and overall survival (OS) between the two risk subgroups, and evaluate whether this artificial intelligence prediction system can help clinicians identify patients who may benefit from postoperative adjuvant therapy. No new experimental drugs or interventional treatments were provided to participants; all data were retrospectively extracted from archived medical records under institutional ethics approval, with waived written informed consent for de-identified historical samples and images.

Conditions

Hepatocellular Carcinoma (HCC)

Outcome Measures

Primary Outcomes (1)

• Recurrence-Free Survival (RFS)

  Time from surgical resection to first local/regional recurrence, distant metastasis or all-cause death, whichever occurs first

  Up to 60 months after hepatectomy

Study Arms (2)

MPDS High-risk patients (risk score > -1.76)

MPDS Low-risk patients (risk score ≤ -1.76)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of 555 adult patients with pathologically confirmed hepatocellular carcinoma who underwent curative hepatectomy. All subjects had complete preoperative gadoxetic acid-enhanced MRI, digital pathological whole-slide images, clinical records and long-term follow-up data. Cases were retrospectively collected from three Chinese tertiary hospitals and the public TCGA-LIHC database, excluding patients with incomplete imaging, pathological or follow-up information.

You may qualify if:

• patients with pathologically confirmed hepatocellular carcinoma (HCC);
• patients accepting curative surgical resection (SR) without preoperative adjuvant treatment;
• MRI were performed two weeks before surgery.

You may not qualify if:

• incomplete clinical information;
• incomplete or suboptimal quality of preoperative MRI imaging data;
• unavailable or poor-quality pathological whole slide images (WSIs);
• incomplete follow-up data.

Sponsors & Collaborators

• Anhui Provincial Hospital: lead

Study Sites (1)

The First Affiliated Hospital of University of Science and Technology of China

Hefei, Anhui, 230000, China

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: July 7, 2026
• First Posted: July 13, 2026
• Study Start: January 1, 2020
• Primary Completion: December 31, 2024
• Study Completion: January 1, 2026
• Last Updated: July 13, 2026

Record last verified: 2026-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)